

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39042-0036		SERIAL NO. 10/579,088			
		APPLICANT: Manzer Durrani					
		FILING DATE: 11/11/2004		GROUP:			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	4,150,071	04-17-79	Pecina				
	4,198,969	04-22-80	Virag				
	4,253,468	03-03-81	Lehmbeck				
	4,301,970	11-24-81	Craighero				
	4,453,542	06-12-84	Hughes				
	4,599,311	07-08-86	Kawasaki				
	4,620,670	11-04-86	Hughes				
	4,732,973	03-22-88	Barr, et al.				
	4,931,373	06-05-90	Kawasaki, et al.				
	5,093,316	03-03-1992	Lezdey, et al.				
	5,134,119	07-28-92	Lezdey, et al.				
	5,150,071	09-22-92	Bouzidi				
	5,166,134	11-24-92	Lezdey, et al.				
	5,218,091	06-08-93	Kawasaki, et al.				
	5,618,786	04-08-97	Roosdorp, et al.				
	4,711,848	12-08-87	Insley, et al.				
	5,780,440	07-14-98	Lezdey, et al.				
	5,993,783	11-30-99	Eljamal, et al.				
	2001/006939	07-05-01	Niven, et al.				
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0289 336 A	11-02-88	EP			<input type="checkbox"/>	<input type="checkbox"/>
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39042-0036	SERIAL NO. 10/579,088
	APPLICANT: Manzer Durrani	
	FILING DATE: 11/11/2004	GROUP:
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Carlson, et al., J. Clin. Invest., Vol. 83, pp. 1183-1190, 1989	
	Carrell, et al., Nature, Vol. 298, pp. 329-334, 1982	
	Carter, et al., Nucleic Acids Research, Vol. 13, No. 12, pp. 4431-4443, 1985	
	Development and Manufacture of Protein Pharmaceuticals, Edited by Steven Nail and Michael J. Akers, Pharmaceutical Biotechnology, Vol. 14, Kluwer Academic/Plenum Publishers, pp. 65-66, 2002	
	Dycaico, et al., Science, Vol. 242, No. 4884, pp. 1409-1412, 1988	
	Gadek, et al., The Metabolic Basis of Inherited Disease (Stanbury, J.B. et al., Eds.) McGraw-Hill, New York, pp. 1450-1467, 1982	
	GenBank Accession No. AAB59375	
	Handbook of Pharmaceutical Additives 2 nd Edition, Compiled by Michael and Irene Ash, Synapse Information Resources, Inc. pp. 797-798, 2002	
	Hunnighake, et al., Am. Rev. Respir. Dis., Vol. 128, pp. 833-838 1983	
	Lomas, et al., Nature, Vol. 357, pp. 605-607, 1992	
	Neddeleman & Wunsch, J. Mol. Biol., Vol. 48, p. 443-453, 1970	
	Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA, Vol. 85, p. 2444-2448, 1988	
	Practical Approaches to Protein Formulation Development, Byeong Chang and Susan Henderson, Rational Design of Stable Protein Formulations: Theory and Practice, Edited by John F. Carpenter and Mark C. Manning, Pharmaceutical Biotechnology Vol. 13, Kluwer Academic/Plenum Publishers, pp. 1-20, 2002	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39042-0036	SERIAL NO. 10/579,088
	APPLICANT: Manzer Durrani	
	FILING DATE: 11/11/2004	GROUP:
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Smith & Waterman, Adv. Appl. Math., Vol. 2, p. 482, 1981	
	Smith, et al., J. Clin. Invest., Vol. 84, pp. 1145-1154, 1989	
	Surfactant-Protein Interactions, Theodore W. Randolph, LaToya S. Jones, Rational Design of Stable Protein Formulations: Theory and Practice, Edited by John F. Carperter and Mark C. Manning, Pharmaceutical Biotechnology, Vol. 13, Kluwer Academic/Plenum Publishers, p. 159-171, 2002	
	Wells, et al., Gene, Vol. 34, p. 315-323, 1985	
	Wells, et al., Philos Trans. R. Soc. London SerA, Vol. 317, p. 415-423, 1986	
	Wu, et al., Proc. Natl. Acad. Sci., Vol. 91, pp. 9014-9018, 1994	
	Zoller, et al., Nucleic Acids Research, Vol. 10, No. 20, p. 6487, 1982	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.